CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
Michael R Migden, Sunandana Chandra, Guilherme Rabinowits, Chieh-I Chen, Jigar Desai, Alex Seluzhytsky, Medha Sasane, Benedetta Campanelli, Zhen Chen, Morganna L Freeman, Sherrif F Ibrahim, Nikhil I Khushalani, Michael Andria, Emily Ruiz, Michael R Migden, Sunandana Chandra, Guilherme Rabinowits, Chieh-I Chen, Jigar Desai, Alex Seluzhytsky, Medha Sasane, Benedetta Campanelli, Zhen Chen, Morganna L Freeman, Sherrif F Ibrahim, Nikhil I Khushalani, Michael Andria, Emily Ruiz
Abstract
In 2018, cemiplimab-rwlc became the first systemic treatment approved by the US FDA for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In 2019, conditional approvals were granted by Health Canada and the European Commission for the same indications. Limited data exist pertaining to the clinical characteristics, disease progression and survivorship of patients with advanced CSCC in real-world clinical practice. CemiplimAb-rwlc Survivorship and Epidemiology (CASE) is a prospective Phase IV, noninterventional, survivorship and epidemiology study that will enroll patients with advanced CSCC who have recently initiated or who plan to receive cemiplimab in a real-world setting. Trial registration number: NCT03836105.
Keywords: CSCC; PD-1 inhibitor; advanced CSCC; cemiplimab; cutaneous squamous cell carcinoma; epidemiology; real-world data; survivorship.
Source: PubMed